Published • loading... • Updated
Ozempic to Lose Weight, Why a Collective Complaint Raises the Risk of Cancer Among Users
Summary by Melty
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The injectable drug that promises to melt the kilos is now on the bench of the accused. A collective complaint is being prepared in France, while appeals are being made in North America, and a word crystallises the anxieties of the users: cancer. At the heart of the controversy, a treatment diverted from its initial indication of diabetes to the "slimbing pit" widely popularized on social networks. This treatment, is Ozempic, a GLP-1 agonist man…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
